Self-emulsifying cannabidiol formulations
The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.
1. A self-emulsifying cannabidiol composition comprising from about 1% to about 40% w/w cannabidiol, from about 40% to about 99% w/w of one or more surfactants selected from polyethylene glycol 40 hydrogenated castor oil, caprylocaproyl polyoxyl-8 glycerides, linoleoyl polyoxyl-6 glycerides, polyglyceryl-3 dioleate, and polysorbate 80, and one or more cosolvents selected from propylene glycol and ethanol, wherein w/w denotes weight by total weight of the composition, and wherein said composition forms an emulsion having an average globule size from about 30 to about 600 nanometers when dispersed in an aqueous medium.
2. The composition on of claim 1 , further comprising one or more oils selected from glyceryl monolinoleate, glyceryl monooleate, propylene glycol dicaprylocaprate, glycerol monostearate 40-55 and a medium chain triglyceride.
3. The composition of claim 1 , further comprising one or more antioxidants selected from alpha tocopherol, butylated hydroxy anisole, butylated hydroxy toluene, ascorbyl palmitate, ascorbic acid, sodium ascorbate, sodium metabisulfite, EDTA, citric acid, sodium bisulfite, sodium thiosulfate, thioglycerol and propyl gallate.
4. The composition of claim 1 , wherein the composition forms an emulsion having an average globule size from about 100 to about 300 nanometers when dispersed in an aqueous medium.
5. The composition of claim 4 , wherein the aqueous medium is gastric fluid.
6. The composition of claim 1 , wherein the composition is suitable for delivery to a gastrointestinal tract or a mucosa of an oral cavity.
7. The composition of claim 1 , wherein the composition is contained in a hard gelatin or soft gelatin capsule.
8. A self-emulsifying cannabidiol composition comprising:
from about 5% to about 35% w/w cannabidiol;
from about 2% to about 60% w/w polyethylene glycol 40 hydrogenated castor oil;
from about 2% to about 50% w/w of a surfactant selected from caprylocaproyl polyoxyl-8 glycerides, linoleoyl polyoxyl-6 glyceride or a combination thereof;
from about 0.1% to about 2% w/w alpha tocopherol;
from about 5% to about 30% w/w of a cosolvent selected from propylene glycol, ethanol and a combination thereof; and
from about 1% to about 15% w/w polyglyceryl-3 dioleate,
wherein w/w denotes weight by total weight of the composition.
9. The composition of claim 8 , wherein the polyethylene glycol 40 hydrogenated castor oil is at a concentration from about 10% to about 50% w/w and the surfactant selected from caprylocaproyl polyoxyl-8 glycerides, linoleoyl polyoxyl-6 glyceride or a combination thereof is at a concentration from about 20% to about 40% w/w.
10. The composition of claim 8 , wherein the composition forms an emulsion with an average globule size from about 100 to about 1,000 nanometers when dispersed in an aqueous medium.
11. The composition of claim 8 , wherein the composition forms an emulsion in less than 30 minutes upon contact with an aqueous medium including gastric fluid.
12. A self-emulsifying cannabidiol composition comprising:
about 20.5% w/w cannabidiol;
about 12.0% w/w ethanol,
about 9.0% w/w propylene glycol;
about 17.0% w/w polyethylene glycol 40 hydrogenated castor oil,
about 26.0% w/w caprylocaproyl polyoxy-8 glycerides;
about 4.0% w/w polyoxyl-6 glycerides; and
about 0.4% w/w alpha tocopherol,
wherein w/w denotes weight by total weight of the composition and wherein the composition forms an emulsion with an average globule size of about 201 nanometers when dispersed in an aqueous medium.
13. A method of treating a disease selected from Prader-Willi syndrome, obesity, graft versus host disease, gelastic seizures/hypothalamic hamartoma neonatal seizures, dystonia, central pain syndromes, phantom limb pain, multiple sclerosis, traumatic brain injury, radiation therapy, acute graft versus host disease, chronic graft versus host disease, T-cell autoimmune disorders, colitis, Dravet Syndrome, Lennox Gastaut Syndrome, mycolonic seizures, juvenile mycolonic epilepsy, refractory epilepsy, childhood absence epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumors, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, Alzheimer's Disease, autism, acne, Parkinson's disease, social anxiety disorder, depression, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, ischemic injury of heart, ischemic injury of brain, chronic pain syndrome, and rheumatoid arthritis comprising administering a composition of claim 1 to a subject in need thereof.
14. A method of treating withdrawal symptoms comprising administering a composition of claim 1 to a subject in need thereof, wherein the withdrawal symptoms are caused by the subject reducing or quitting use of an opioid, cocaine, heroin, an amphetamine or nicotine.